High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study
Packard, Samuel E
Sherrill, Duane L
Martinez, Fernando D
AffiliationUniv Arizona, Asthma & Airway Dis Res Ctr
Univ Arizona, Coll Med, Dept Pharmacol
MetadataShow full item record
PublisherEUROPEAN RESPIRATORY SOC JOURNALS LTD
CitationNenna, R., Zhai, J., Packard, S. E., Spangenberg, A., Sherrill, D. L., Martinez, F. D., ... & Guerra, S. (2020). High cytomegalovirus serology and subsequent COPD-related mortality: a longitudinal study. ERJ open research, 6(2).
JournalERJ OPEN RESEARCH
RightsCopyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBackground: Positive serology for cytomegalovirus (CMV) has been associated with all-cause mortality risk but its role in COPD mortality is unknown. The objective of the present study was to assess the relationship between CMV serology and COPD mortality. Methods: We analysed data from 806 participants in the Tucson Epidemiological Study of Airway Obstructive Disease who, at enrolment, were aged 28-70 years and had completed lung function tests. We tested CMV serology in sera from enrolment and defined "high CMV serology" as being in the highest tertile. Vital status, date and cause of death were assessed through death certificates and/or linkage with the National Death Index up to January 2017. The association of CMV serology with all-cause and causespecific mortality risk was tested in Cox models adjusted for age, sex, level of education, body mass index, smoking status and pack-years. Results: High CMV serology was marginally associated with all-cause mortality (p=0.071) but the effect was inversely dependent on age, with the association being much stronger among participants <55 years than among participants.55 years at enrolment ( p-value for CMV-by-age interaction <0.001). Compared with low CMV serology, high CMV serology was associated with mortality from COPD among all subjects (adjusted hazard ratio (HR) 2.38, 95% CI 1.11-5.08; p=0.025) and particularly in subjects <55 years old at enrolment (HR 5.40, 95% CI 1.73-16.9; p=0.004). Consistent with these results, high CMV serology also predicted mortality risk among subjects who already had airflow limitation at enrolment (HR 2.10, 95% CI 1.20-3.68; p=0.009). Conclusions: We report a strong relationship between CMV serology and the risk of dying from COPD, and thus identify a novel risk factor for COPD mortality.
NoteOpen access journal
VersionFinal published version
Except where otherwise noted, this item's license is described as Copyright ©ERS 2020. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
- Serum concentrations of club cell secretory protein (Clara) and cancer mortality in adults: a population-based, prospective cohort study.
- Authors: Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martinez FD
- Issue date: 2013 Dec
- Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children.
- Authors: Hussain T, Burch M, Fenton MJ, Whitmore PM, Rees P, Elliott M, Aurora P
- Issue date: 2007 Apr 3
- Asthma, airflow limitation and mortality risk in the general population.
- Authors: Huang S, Vasquez MM, Halonen M, Martinez FD, Guerra S
- Issue date: 2015 Feb
- Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort.
- Authors: Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ
- Issue date: 2013 May
- Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk.
- Authors: Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD
- Issue date: 2009 Oct